Literature DB >> 12714805

In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinobacter baumannii.

Felipe Fernández-Cuenca1, Luis Martínez-Martínez, Alvaro Pascual, Evelio J Perea.   

Abstract

The in vitro activity of the two-drug combinations of azithromycin with amikacin, ceftazidime, ciprofloxacin or imipenem against five clonally unrelated strains of Acinobacter baumannii were evaluated. Synergy studies were performed by the checkerboard microtiter method. The fractional inhibitory concentration (FIC) index was calculated for each drug combination. None of the four combinations tested was antagonistic. The combination of azithromycin and ceftazidime was synergistic (FIC index <or=0.5) for one strain and partially synergistic (FIC index 0.75) for another strain. An additive effect (FIC index = 1) was observed for the combinations of azithromycin with imipenem (two strains) or ceftazidime (one strain). The activities of the other combinations were indifferent (FIC index range from 1.5 to 2.5). It is concluded that azithromycin combined with ceftazidime has moderate synergistic activity against some multiresistant A. baumannii. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714805     DOI: 10.1159/000069774

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  9 in total

1.  Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test.

Authors:  F A Haddad; K Van Horn; C Carbonaro; M Aguero-Rosenfeld; G P Wormser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

Review 2.  Mechanisms of drug combinations: interaction and network perspectives.

Authors:  Jia Jia; Feng Zhu; Xiaohua Ma; Zhiwei Cao; Zhiwei W Cao; Yixue Li; Yixue X Li; Yu Zong Chen
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

Review 3.  Carbapenems: past, present, and future.

Authors:  Krisztina M Papp-Wallace; Andrea Endimiani; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

Review 4.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

5.  Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii.

Authors:  Koichi Yamada; Katsunori Yanagihara; Norihito Kaku; Yosuke Harada; Yohei Migiyama; Kentaro Nagaoka; Yoshitomo Morinaga; Shigeki Nakamura; Yoshifumi Imamura; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Hiroo Hasegawa; Hiroshige Mikamo; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

Review 6.  Treatment options for multidrug-resistant Acinetobacter species.

Authors:  Jacob Gilad; Yehuda Carmeli
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Synergy Between Proline-Rich Antimicrobial Peptides and Small Molecule Antibiotics Against Selected Gram-Negative Pathogens in vitro and in vivo.

Authors:  Laszlo Otvos; Eszter Ostorhazi; Dora Szabo; Steven D Zumbrun; Lynda L Miller; Stephanie A Halasohoris; Puvi D Desai; Sharon M Int Veldt; Carl N Kraus
Journal:  Front Chem       Date:  2018-08-14       Impact factor: 5.221

8.  Discerning the role of polymyxin B nonapeptide in restoring the antibacterial activity of azithromycin against antibiotic-resistant Escherichia coli.

Authors:  Farah Al-Marzooq; Akela Ghazawi; Saeed Tariq; Lana Daoud; Timothy Collyns
Journal:  Front Microbiol       Date:  2022-09-21       Impact factor: 6.064

Review 9.  Multitarget Approaches against Multiresistant Superbugs.

Authors:  Declan Alan Gray; Michaela Wenzel
Journal:  ACS Infect Dis       Date:  2020-03-19       Impact factor: 5.084

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.